

1 Semantic computational analysis of anticoagulation use in atrial fibrillation from real world
2 data

3 Daniel M. Bean^{1,2*}, James Teo³, Honghan Wu^{4,5,6}, Ricardo Oliveira⁷, Raj Patel⁸, Rebecca
4 Bendayan^{1,9}, Ajay M. Shah^{10,11}, Richard J. B. Dobson^{1,2,9,12}, Paul A. Scott^{10,11*}

5 **Author affiliations**

- 6 1. Department of Biostatistics and Health Informatics, Institute of Psychiatry,
7 Psychology and Neuroscience, King's College London, London, U.K.
- 8 2. Health Data Research UK London, University College London, London, U.K.
- 9 3. Department of Stroke and Neurology, King's College Hospital NHS Foundation
10 Trust, London, U.K.
- 11 4. Centre for Medical Informatics, Usher Institute, University of Edinburgh, U.K.
- 12 5. School of Computer and Software, Nanjing University of Information Science and
13 Technology, Nanjing, China
- 14 6. Health Data Research UK Scotland, Edinburgh, UK
- 15 7. Unidade de Doenças Imunomediadas Sistémicas (UDIMS), S. Medicina IV, Hospital
16 Prof. Doutor Fernando Fonseca, Amadora Portugal
- 17 8. Department of Haematology, King's College Hospital NHS Foundation Trust,
18 London, U.K.
- 19 9. NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation
20 Trust and King's College London, London, U.K.
- 21 10. British Heart Foundation Centre, King's College London, London, U.K.
- 22 11. Department of Cardiology, King's College Hospital NHS Foundation Trust, London,
23 U.K.
- 24 12. Institute of Health Informatics, University College London, London, U.K.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25

26 ***Corresponding authors**

27 Email: paulscott3@nhs.net (PAS); daniel.bean@kcl.ac.uk (DMB)

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43 **Abstract**

44 Atrial fibrillation (AF) is the most common arrhythmia and significantly increases stroke risk.

45 This risk is effectively managed by oral anticoagulation. Recent studies using national
46 registry data indicate increased use of anticoagulation resulting from changes in guidelines
47 and the availability of newer drugs.

48 The aim of this study is to develop and validate an open source risk scoring pipeline for free-
49 text electronic health record data using natural language processing.

50 AF patients discharged from 1st January 2011 to 1st October 2017 were identified from
51 discharge summaries (N=10,030, 64.6% male, average age 75.3 ± 12.3 years). A natural
52 language processing pipeline was developed to identify risk factors in clinical text and
53 calculate risk for ischaemic stroke (CHA₂DS₂-VASc) and bleeding (HAS-BLED). Scores
54 were validated vs two independent experts for 40 patients.

55 Automatic risk scores were in strong agreement with the two independent experts for
56 CHA₂DS₂-VASc (average kappa 0.78 vs experts, compared to 0.85 between experts).
57 Agreement was lower for HAS-BLED (average kappa 0.54 vs experts, compared to 0.74
58 between experts).

59 In high-risk patients (CHA₂DS₂-VASc ≥ 2) OAC use has increased significantly over the last
60 7 years, driven by the availability of DOACs and the transitioning of patients from AP
61 medication alone to OAC. Factors independently associated with OAC use included
62 components of the CHA₂DS₂-VASc and HAS-BLED scores as well as discharging specialty
63 and frailty. OAC use was highest in patients discharged under cardiology (69%).

64 Electronic health record text can be used for automatic calculation of clinical risk scores at
65 scale. Open source tools are available today for this task but require further validation.

66 Analysis of routinely-collected EHR data can replicate findings from large-scale curated
67 registries.

68

69 **Keywords**

70 Natural language processing, electronic health records

71 **Abbreviations**

72 AF = atrial fibrillation

73 AP = antiplatelet

74 DOAC = direct oral anticoagulant

75 EHR = electronic health record

76 NLP = natural language processing

77 OAC = oral anticoagulant

78 **Introduction**

79 Atrial fibrillation (AF) affects 2% of the UK population and significantly increases stroke
80 risk.[1] Although this risk can be substantially reduced by oral anticoagulants (OAC),
81 warfarin has historically been underused in AF. Over the last decade the antithrombotic
82 landscape has changed significantly with: (1) the introduction of direct oral anticoagulants
83 (DOACs), and (2) the updated UK NICE 2014 AF guidelines[2] which introduced the
84 CHA₂DS₂-VASc[3] and HAS-BLED[4] risk calculators and removed endorsement of the use
85 of antiplatelet agents for stroke prevention. A number of large-scale observational studies
86 have found that rates of OAC use have significantly increased since the introduction of
87 DOACs.[5–8] However, these previous analyses have used structured data, which do not
88 capture the full clinical narrative, and many studies have used registry data which can be
89 costly and time-consuming to collect and may not always accurately reflect real-world
90 practice.

91 An alternative approach to observational research is the use of Electronic Health Record
92 (EHRs) data generated as part of routine clinical care.[9] Modern EHRs contain a
93 combination of structured (e.g. age, sex) and unstructured (e.g. free text, image) data. Whilst
94 free text is information-dense to a human reader, to be useful for computational analysis it
95 requires conversion to a structured format. Performing this process manually is very labour-
96 intensive. However, given the enormous volume of clinical data contained solely in written
97 notes[10], extracting this information is critical to realizing the full potential of EHRs.

98 Natural language processing (NLP) uses computer algorithms to identify key elements in
99 everyday language and extract meaning from spoken or written language. NLP can be used to
100 convert unstructured text found in EHRs to structured data. This should allow rapid, low-cost

101 and automated analysis of medical text, including the generation of observational data for
102 research purposes.

103 In this study we develop an NLP pipeline to calculate clinical risk scores from free text. We
104 build upon our existing data pooling, harmonization and information retrieval tool
105 (CogStack[11,12]), together with a semantic NLP tool for information extraction
106 (SemEHR[13,14]). Previous studies have found it is possible to accurately predict CHA₂DS₂-
107 VASc using EHR text.[15–17] We build on this work to develop a flexible open source
108 pipeline and calculate additional risk scores. Our specific objectives are to:

- 109 a) Develop and validate an NLP risk scoring pipeline.
- 110 b) Explore trends in antithrombotic medication use for AF including the impact
111 of the availability of DOACs and changes in NICE 2014 guidelines.
- 112 c) Quantify the association between antithrombotic medication use and relevant
113 clinical patient-level variables.

114

115 **Methods**

116 **Data, materials and code**

117 A subset of the dataset limited to anonymisable information (e.g. only UMLS codes and
118 demographics) is available on request to researchers with suitable training in information
119 governance and human confidentiality protocols; contact jamesteo@nhs.net. All code for
120 calculating risk scores is open-source in GitHub at [https://github.com/CogStack/risk-score-](https://github.com/CogStack/risk-score-builder)
121 [builder](https://github.com/CogStack/risk-score-builder) . Source text from patient records used in the study will not be available due to
122 inability to fully anonymise up to the Information Commissioner Office (ICO) standards.
123 Risk factor-level data is available as S3 Table.

124

125 **Ethical approval**

126 This study was performed on anonymised data as a clinical audit for service evaluation. The
127 project was reviewed by the King's College Hospital Information Governance committee
128 chaired by the Caldicott Guardian Professor Alastair Baker (the Caldicott Guardian is the
129 statutory individual responsible for protecting the confidentiality of health and care
130 information in a UK healthcare organisation) and approval was granted in November 2018
131 with continued oversight. The legal basis of secondary use was analysis for service
132 evaluation, operational performance and clinical audit.

133

134 **Cohort selection**

135 We used an open-source retrieval system for unstructured clinical data (CogStack)[11,12] to
136 define a cohort of patients aged ≥ 18 with AF admitted to KCH between 01-01-2011 and 01-

137 10-2017. We searched discharge summaries for adult inpatients discharged alive containing
138 the exact keywords “AF”, “PAF”, “AFib” or “Atrial Fibrillation”. Although the risk of stroke
139 and OAC indications in atrial flutter are similar to AF, in clinical practice in the UK many
140 patients with isolated typical flutter undergo flutter ablation after which there is significant
141 variation in practice in terms of long-term OAC prescription. For this reason we decided not
142 to include patients with flutter. Patients with missing data such as gender or discharge ward
143 were excluded (N=397). We also excluded patients discharged directly from the emergency
144 department, day units or the clinical decision unit, as these did not constitute an inpatient
145 admission and did not generate the discharge summaries we used to identify discharge
146 medication and diagnosis of AF.

147

148 We further refined our cohort using an NLP pipeline SemEHR[13,14] which generates
149 semantic annotation and can detect negation, temporality (current, historic) and experiencer.
150 We excluded patients for which the NLP pipeline detected negation, a hypothetical mention
151 or another experiencer (the mention refers to another individual who is not the patient e.g.
152 family history) for AF.

153

154 We defined a new diagnosis of AF as the first mention of AF in a patient with at least one
155 previous visit and no earlier record of AF or prescription of antithrombotic medication.

156

157 **CHA₂DS₂-VASc and HAS-BLED risk score calculation**

158 We used the SemEHR NLP pipeline to annotate clinical documents with Unified Medical
159 Language System (UMLS) concepts.[18] To calculate CHA₂DS₂-VASc and HAS-BLED risk
160 scores, we manually mapped each phenotypic component of the score (e.g. stroke) to the

161 closest general term in the Human Phenotype Ontology (HPO)[19] and automatically
162 included all descendent terms in the ontology. All HPO concepts were then mapped
163 automatically to UMLS. Medications were manually mapped to UMLS concepts directly (as
164 they are not present in HPO), and the first child terms are included automatically using
165 UMLS concept relationships. The only factor not included was a labile International
166 Normalised Ratio (INR) in the HAS-BLED score, which is not in HPO and is ambiguous in
167 UMLS, and which is not reliably recorded in the dataset.

168
169 The result is a mapping of each score component to a list of UMLS concepts, which was
170 manually refined based on manual review of a random sample of 205 patients by a single
171 annotator. The final mapping is available as S1 Table. For each component we then identified
172 matching annotations in medical records using the NLP pipeline and awarded points as
173 defined for each score.

174
175 For patients with multiple admissions (and the possibility of change in risk scores over time)
176 we used the most recent admission to calculate risk scores.

177

178 **Antithrombotic Drug Prescription**

179 Antithrombotic prescriptions of OACs (apixaban, rivaroxaban, dabigatran, edoxaban,
180 warfarin) and antiplatelets (AP; aspirin, clopidogrel, dipyridamole, ticagrelor, prasugrel) were
181 extracted from free text discharge summaries. This was performed using a custom NLP
182 pipeline written in Python and specifically adapted to the KCH record structure. Drug
183 mentions are identified by fuzzy matching and any detected mentions are tested for negation
184 using regular expressions. The open source code is available at
185 <https://github.com/CogStack/OAC-NLP> .

186

187 **Hospital Frailty Risk Score (HFRS) Calculation**

188 We calculated the Hospital Frailty Risk Score (HFRS) proposed by Gilbert *et al.* [20] which
189 uses ICD-10 diagnostic codes to identify a group of patients at higher risk of adverse
190 outcomes. We mapped these ICD-10 codes to UMLS concept unique identifiers (CUI) using
191 bio-ontology.[21] We used SemEHR to detect all UMLS concepts in free text and calculate
192 the total frailty risk as the sum of concept weights as defined by Gilbert *et al.*.[20]

193

194 **Validation of AF diagnosis, Antithrombotic drug prescription and** 195 **NLP risk scores**

196 The diagnosis of AF and antithrombotic drug prescriptions were manually validated on a
197 random sample of 300 discharge summaries (AF diagnosis) or 200 discharge summaries
198 (prescription) taken from our cohort. Performance was measured by calculating the precision,
199 recall and F1 score.

200

201 CHA₂DS₂-VASc and HAS-BLED risk scores were validated for a sample of 40 patients
202 selected at random after stratification by gender and age (this sample does not overlap with
203 the initial sample used to refine the automated scoring). Each patient was manually scored for
204 all components of CHA₂DS₂-VASc and HAS-BLED by two independent expert clinicians
205 according to agreed criteria (see S1 Table). Inter-annotator agreement for the final scores was
206 calculated using a weighted Cohen's kappa. Given the high-dimensional complexity of the
207 HFRS, we did not attempt to validate it and instead compared the score distribution to the
208 original findings of Gilbert *et al.*.[20]

209

210 **Statistical analysis**

211 Categorical variables are expressed as percentages and compared using a chi-squared test.

212 Normally distributed continuous variables are expressed as mean+/-standard deviation and

213 compared using Student *t* test. Skewed continuous variables (length of stay, number of visits,

214 HFRS) are expressed as median (minimum-maximum) and compared using a Kruskal-Wallis

215 H-test. Statistical analyses were performed using the StatsModels and scipy libraries in

216 Python. In all analyses a $P<0.05$ was considered significant.

217

218 We evaluated temporal trends in the rates of prescription of antithrombotic drugs for patients

219 at high stroke risk ($\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$) using linear regression with quarterly data,

220 retaining the last visit per quarter for each patient.

221

222 The association of individual risk score ($\text{CHA}_2\text{DS}_2\text{-VASc}$ and HAS-BLED) components and

223 other clinical variables with antithrombotic prescription were evaluated in univariate and

224 multivariate analyses. Factors with a significant association ($P<0.05$) in univariate analysis

225 were entered into multivariate models. These associations were estimated using odds ratios

226 from logistic regression. Uncontrolled hypertension and concomitant alcohol abuse were not

227 included in the models as there were too few positive cases in our validation data.

228 Concomitant drugs increasing bleeding risk were also excluded as this includes antiplatelets

229 which could be prescribed for anticoagulation.

230

231

232 Results

233 Cohort identification

234 We identified 11,260 adult patients admitted to KCH with a diagnosis of AF. After excluding
 235 1,230 patients (Fig 1) we were left with a final cohort of 10,030 patients admitted 17,387
 236 times during the prescribing study period and 151,174 times in total (Table 1).

237

238

239 **Fig 1. Derivation of the study cohort.** AF = Atrial fibrillation, NLP = natural language
 240 processing.

241

242 **Table 1. Baseline characteristics of study cohort.**

<i>Factor</i>		<i>Total (n=10030)</i>	<i>Any OAC (n=5287)</i>	<i>Warfarin (n=3328)</i>	<i>DOAC (n=1873)</i>	<i>AP only (n=1902)</i>	<i>No Antithrombotic medication (n=1998)</i>	<i>P-value</i>
<i>Other clinical variables</i>	Age (y)	75.3 ± 12.3	75.1 ± 11.5	74.4 ± 11.1	76.4 ± 12.1	77.5 ± 12.5	74.5 ± 14.3	<0.001
	Frailty (HFRS)	2.5 (0.0-28.1)	2.0 (0.0-28.1)	1.8 (0.0-23.0)	3.2 (0.0-28.1)	3.2 (0.0-20.5)	3.2 (0.0-28.1)	<0.001
	LOS (days)	6.5 (0.0-390.0)	6.2 (0.0-360.4)	6.2 (0.0-326.2)	6.2 (0.0-360.4)	6.4 (0.0-253.7)	5.8 (0.0-390.0)	0.019
	Previous admissions (n)	7.0 (1.0-242.0)	8.0 (1.0-242.0)	7.0 (1.0-178.0)	9.0 (1.0-242.0)	6.0 (1.0-215.0)	8.0 (1.0-189.0)	<0.001
<i>CHA2DS2-VASc factors</i>	Congestive heart failure	3238 (32.3%)	1992 (37.7%)	1254 (37.7%)	711 (38.0%)	529 (27.8%)	511 (25.6%)	<0.001
	Diabetes mellitus	5722 (57.0%)	3222 (60.9%)	2044 (61.4%)	1125 (60.1%)	984 (51.7%)	976 (48.9%)	<0.001
	Female	4351 (43.4%)	2277 (43.1%)	1371 (41.2%)	866 (46.2%)	911 (47.9%)	886 (44.3%)	<0.001
	Hypertension	6828 (68.1%)	3664 (69.3%)	2226 (66.9%)	1376 (73.5%)	1323 (69.6%)	1256 (62.9%)	<0.001
	Stroke	4824 (48.1%)	2607 (49.3%)	1528 (45.9%)	1028 (54.9%)	967 (50.8%)	952 (47.6%)	<0.001
	Vascular disease	3132 (31.2%)	1710 (32.3%)	1082 (32.5%)	600 (32.0%)	562 (29.6%)	429 (21.5%)	<0.001
	0	156 (1.6%)	58 (1.1%)	29 (0.9%)	29 (1.6%)	22 (1.2%)	72 (3.6%)	

CHA2DS₂-VASc score	1	392 (3.9%)	168 (3.2%)	118 (3.5%)	46 (2.5%)	78 (4.1%)	112 (5.6%)	
	2	932 (9.3%)	451 (8.5%)	306 (9.2%)	143 (7.6%)	171 (9.0%)	207 (10.4%)	
	3	1405 (14.0%)	707 (13.4%)	482 (14.5%)	214 (11.4%)	227 (11.9%)	312 (15.6%)	
	4	1700 (16.9%)	891 (16.9%)	608 (18.3%)	268 (14.3%)	303 (15.9%)	345 (17.3%)	
	5	1853 (18.5%)	1001 (18.9%)	625 (18.8%)	364 (19.4%)	370 (19.4%)	338 (16.9%)	
	6	1651 (16.5%)	899 (17.0%)	540 (16.2%)	337 (18.0%)	338 (17.8%)	310 (15.5%)	
	7	1138 (11.3%)	628 (11.9%)	350 (10.5%)	269 (14.4%)	249 (13.1%)	180 (9.0%)	
	8	613 (6.1%)	371 (7.0%)	211 (6.3%)	153 (8.2%)	115 (6.0%)	92 (4.6%)	
	9	190 (1.9%)	113 (2.1%)	59 (1.8%)	50 (2.7%)	29 (1.5%)	30 (1.5%)	
	Total	4.7 ± 2.0	4.8 ± 2.0	4.7 ± 1.9	5.0 ± 2.0	4.8 ± 2.0	4.3 ± 2.1	<0.001
HAS-BLED factors*	Abnormal liver function	532 (5.3%)	240 (4.5%)	150 (4.5%)	89 (4.8%)	97 (5.1%)	176 (8.8%)	<0.001
	Abnormal renal function	1706 (17.0%)	937 (17.7%)	539 (16.2%)	380 (20.3%)	307 (16.1%)	355 (17.8%)	<0.001
	Alcohol	75 (0.8%)	75 (1.4%)	26 (0.8%)	47 (2.5%)	0 (0.0%)	0 (0.0%)	<0.001
	Bleeding	1429 (14.2%)	604 (11.4%)	348 (10.5%)	241 (12.9%)	269 (14.1%)	483 (24.2%)	<0.001
	Drugs increasing bleed risk	3504 (34.9%)	3504 (66.3%)	2130 (64.0%)	1317 (70.3%)	-	-	-
HAS-BLED score	0	681 (6.8%)	204 (3.9%)	141 (4.2%)	62 (3.3%)	148 (7.8%)	194 (9.7%)	
	1	2716 (27.1%)	1053 (19.9%)	723 (21.7%)	314 (16.8%)	650 (34.2%)	638 (31.9%)	
	2	3528 (35.2%)	1780 (33.7%)	1186 (35.6%)	568 (30.3%)	783 (41.2%)	721 (36.1%)	
	3	2190 (21.8%)	1488 (28.1%)	866 (26.0%)	596 (31.8%)	267 (14.0%)	359 (18.0%)	
	4	763 (7.6%)	618 (11.7%)	338 (10.2%)	267 (14.3%)	53 (2.8%)	79 (4.0%)	
	5	135 (1.4%)	127 (2.4%)	65 (1.9%)	59 (3.1%)	1 (0.1%)	7 (0.3%)	
	6	17 (0.2%)	17 (0.3%)	9 (0.3%)	7 (0.4%)	0 (0.0%)	0 (0.0%)	
	Total	2.0 ± 1.1	2.3 ± 1.1	2.2 ± 1.1	2.5 ± 1.1	1.7 ± 0.9	1.8 ± 1.0	<0.001

243 Continuous variables are represented as mean ± standard deviation or median (min-max),
 244 categorical variables are represented as n (%). Hospital Frailty Risk Score (HFRS) is
 245 calculated according to Gilbert et al.[20]. P-value calculated comparing the mutually-
 246 exclusive groups Warfarin, DOAC, AP-only, No Antithrombotic medication. Continuous
 247 variables tested using a Kruskal-Wallis H-test, categorical variables tested using a Chi-

248 *squared test. *uncontrolled hypertension is not shown for HAS-BLED as it was not detected*
249 *for any patients. Stroke is only shown under CHA2DS2-VASc but is a factor for both*
250 *CHA2DS2-VASc and HAS-BLED.*

251

252 **Validation of AF diagnosis, Antithrombotic drug prescription and** 253 **NLP risk scores**

254 A diagnosis of AF was confirmed in 96% of 300 cases reviewed. Of these, 200 cases were
255 manually coded for prescription of any of 10 antithrombotic medications. Five drugs with <5
256 positive examples in the validation sample were excluded (edoxaban, dipyridamole,
257 prasugrel, dabigatran, ticagrelor) due to the small sample size. The pipeline achieved perfect
258 precision and recall for these excluded drugs but the sample size was too small to be
259 meaningful. The average performance over the remaining 5 drugs was 95% precision at 97%
260 recall (Table 2).

261

262 **Table 2. Performance of the drug NLP pipeline in manual validation.**

Drug	Accuracy	Precision	Recall	F1	P	FN	FP	TN	TP
Warfarin	0.94	0.87	0.97	0.92	69	2	10	121	67
Aspirin	0.96	0.90	0.98	0.94	62	1	7	131	61
Rivaroxaban	1.00	1.00	0.95	0.98	22	1	0	178	21
Clopidogrel	1.00	1.00	0.94	0.97	17	1	0	183	16
Apixaban	1.00	1.00	1.00	1.00	13	0	0	187	13
Average	0.98	0.95	0.97	0.96					

263 *Discharge summaries were selected at random (n=200) and manually annotated for the*
264 *prescription of the 10 drugs detected by the pipeline. Performance for the 5 drugs with > 10*
265 *positive examples in manual annotation is shown. P = total positive examples in manual*
266 *annotation, FN = false negative, FP = false positive, TN = true negative, TP = true positive.*

267

268

269 The performance of the automatic NLP scoring procedure was evaluated in 40 patients.

270 Overall the agreement between two human expert raters and the algorithm for CHA₂DS₂-

271 VASc was high for all pairs, and only slightly higher for the two human raters than for the

272 algorithm vs. either expert. HAS-BLED agreement however was lower for all comparisons

273 (Table 3 and S2 Table). Total scores and risk factor-level variables are available as S3 Table.

274

275 **Table 3. Inter-rater agreement statistics for CHA₂DS₂-VASc and HAS-BLED risk**
276 **scores.**

Score	Rater 1	Rater 2	Kappa (95% CI)
CHA ₂ DS ₂ -VASc	Algorithm	Expert A	0.76 (0.65-0.86)
CHA ₂ DS ₂ -VASc	Algorithm	Expert B	0.80 (0.68-0.92)
CHA ₂ DS ₂ -VASc	Expert A	Expert B	0.85 (0.73-0.97)
HAS-BLED	Algorithm	Expert A	0.54 (0.36-0.72)
HAS-BLED	Algorithm	Expert B	0.53 (0.34-0.72)
HAS-BLED	Expert A	Expert B	0.74 (0.51-0.97)

277 *Raters 1 and 2 are two independent clinician raters, Algorithm is the automatic scoring*

278 *pipeline developed in this paper.*

279

280 **Temporal Trends in Antithrombotic drug prescription**

281 Prior to 2013, OAC use varied between 40-45% (mean 43.4%) with no strong trend (linear

282 regression $R^2=0.08$, slope = +0.2% per quarter, Fig 2a,b). From 2013 onwards the average

283 OAC rate remained above 47% and there was a gradual increase in OAC use such that at the

284 end of the study period 68.4% of patients were taking an OAC (linear regression $R^2=0.77$,

285 slope = +1.2% per quarter). This increase in OAC rate is particularly pronounced from 2016

286 onwards (linear regression $R^2=0.86$, slope = +2.7% per quarter). Conversely, the proportion

287 of patients taking an AP drug alone declined significantly from 48.9% at the start to 14.5% at
288 the end of the study, with a consistent linear decrease over the period (linear regression
289 $R^2=0.94$, slope = -1.24% per quarter).

290

291 **Fig 2. Antithrombotic drug prescribing patterns in the AF cohort patients with**

292 **CHA₂DS₂-VASc \geq 2.** A,B) Prescribing rates for all admissions during the study period. A)

293 OAC choice vs. no OAC. B) Prescribing of OAC and/or AP vs. neither. C) Prescribing rates

294 stratified by CHA₂DS₂-VASc for all patients. D) Prescribing rates grouped by HFRS as

295 defined by Gilbert et al. Due to low numbers of patients with score > 20 the final (highest)

296 bin is wider than the others. E) Prescribing rate vs. age at discharge. Points are the mean

297 prescribing rate per year for all ages with \geq 10 patients, a 10-year moving median (trend) is

298 shown as a dashed red line. F) prescribing rates in patients grouped by discharging specialty.

299 In C, D, F the number above each bar indicates the number of patients. AP = antiplatelet,

300 HFRS = hospital frailty risk score, OAC = oral anticoagulant.

301

302

303 At the start of the study warfarin was the only widely available OAC. In 2012 NICE endorsed

304 the use of the first 2 DOACs (Dabigatran and Rivaroxaban) and the prescription of both

305 drugs increased from the end of 2012, at a similar time to when overall OAC use began to

306 rise. From then on there was a gradual increase in the use of DOACs at the expense of

307 warfarin, such that at the end of the study period in 2017 warfarin only contributed a third of

308 all OAC prescriptions.

309

310 For newly diagnosed AF (n=4986) Antithrombotic drug trends closely mirrored those found

311 in the overall AF cohort (Fig 3).

312

313 **Fig 3. Prescribing trends for new AF cases over the study period.** The solid blue line
 314 represents warfarin, the solid pink line represents DOAC, the dashed black line represents AP
 315 prescription without any OAC, the solid green line represents the no drug group. Total N =
 316 4986. AP = antiplatelet, DOAC = direct oral anticoagulant, OAC = oral anticoagulant.

317

318 **Clinical Factors associated with Antithrombotic drug**

319 **prescription**

320 There was gradual increase in rates of OAC use with a higher CHA₂DS₂-VASc score (+1.6%
 321 per point, linear regression R² = 0.93, p < 0.001) (Fig 2c). Conversely OAC prescription
 322 decreased with older age in patients ≥80 years (Fig 2e).

323

324 In multivariate analysis (Table 4) clinical variables associated with a higher rate of OAC use
 325 (vs. no OAC) included heart failure, diabetes and stroke. Factors negatively associated with
 326 OAC use included a history of vascular disease, abnormal liver function and history of
 327 bleeding. Older patients receiving OAC were more likely to be on warfarin vs. DOACs.

328 Higher rates of AP drug use alone (vs. OAC) were associated with the presence of vascular
 329 disease, whereas heart failure, and diabetes were associated with lower rates.

330

331 **Table 4. Univariate and multivariate logistic regression for factors associated with**
 332 **antithrombotic drug prescribing at most recent discharge for patients with CHA₂DS₂-**
 333 **VASc ≥ 2.**

Group	Factor	Any OAC vs no OAC				DOAC vs Warfarin				AP-only vs OAC-only			
		Univariate		Multivariate		Univariate		Multivariate		Univariate		Multivariate	
		OR (95%CI)	P- val ue	OR (95%CI)	P- val ue	OR (95%CI)	P- val ue	OR (95%CI)	P- val ue	OR (95%CI)	P- val ue	OR (95%CI)	P- val ue

Other clinical variables	Age (per 20 years)	0.9 (0.9-1.0)	0.0 39	0.9 (0.8-0.9)	<0.001	1.3 (1.2-1.4)	<0.001	0.8 (0.8-0.9)	<0.001	1.4 (1.2-1.5)	<0.001	1.0 (1.0-1.1)	0.0 80
	LOS (per 14 days)	0.9 (0.9-1.0)	<0.001	1.0 (0.9-1.0)	0.0 16	1.1 (1.1-1.2)	<0.001	1.1 (1.0-1.1)	0.0 25	1.1 (1.0-1.1)	0.0 06	1.0 (1.0-1.1)	0.0 73
	Visits (per 10)	1.1 (1.0-1.1)	<0.001	1.1 (1.1-1.1)	<0.001	1.1 (1.1-1.1)	<0.001	1.0 (1.0-1.1)	0.4 46	0.9 (0.9-1.0)	<0.001	0.9 (0.9-1.0)	<0.001
CHA2DS2-VASc factors	Congestive heart failure	1.7 (1.6-1.8)	<0.001	1.7 (1.5-1.8)	<0.001	1.0 (0.9-1.1)	0.8 99			0.7 (0.6-0.8)	<0.001	0.7 (0.6-0.8)	<0.001
	Diabetes mellitus	1.4 (1.3-1.5)	<0.001	1.2 (1.1-1.3)	<0.001	1.0 (0.9-1.1)	0.9 73			0.8 (0.7-0.9)	<0.001	0.9 (0.8-1.0)	0.0 33
	Female	1.0 (0.9-1.0)	0.3 27			1.2 (1.1-1.4)	0.0 02	1.1 (1.0-1.2)	0.1 69	1.1 (1.0-1.2)	0.2 21		
	Hypertension	1.1 (1.0-1.2)	0.0 42	1.1 (1.0-1.2)	0.1 37	1.4 (1.2-1.5)	<0.001	1.1 (0.9-1.2)	0.2 54	1.1 (1.0-1.2)	0.0 89		
	Stroke	1.1 (1.0-1.2)	0.0 20	1.3 (1.1-1.4)	<0.001	1.4 (1.3-1.6)	<0.001	1.0 (0.9-1.2)	0.6 69	1.0 (0.9-1.1)	0.5 51		
	Vascular disease	1.1 (1.0-1.2)	0.0 18	0.9 (0.8-0.9)	0.0 03	1.0 (0.9-1.1)	0.6 85			1.3 (1.1-1.5)	<0.001	1.6 (1.4-1.9)	<0.001
HAS-BLED factors	Abnormal liver function	0.7 (0.6-0.9)	<0.001	0.7 (0.5-0.8)	<0.001	1.0 (0.8-1.3)	0.9 52			1.1 (0.8-1.4)	0.5 59		
	Abnormal renal function	1.1 (1.0-1.2)	0.1 36			1.3 (1.1-1.5)	0.0 02	1.0 (0.8-1.1)	0.5 94	0.9 (0.8-1.0)	0.1 17		
	Bleeding	0.6 (0.5-0.7)	<0.001	0.6 (0.5-0.6)	<0.001	1.3 (1.1-1.5)	0.0 14	0.9 (0.8-1.2)	0.6 20	1.2 (1.0-1.4)	0.0 81		
Frailty	HFRS (per 10 points)	0.8 (0.7-0.9)	<0.001	0.7 (0.6-0.8)	<0.001	2.6 (2.2-3.0)	<0.001	2.1 (1.8-2.6)	<0.001	1.2 (1.0-1.4)	0.0 15	1.2 (1.0-1.4)	0.0 41
Discharge Location	Stroke	0.6 (0.6-0.7)	<0.001	(reference)		1.4 (1.1-1.6)	<0.001	(reference)		2.2 (1.9-2.5)	<0.001	(reference)	
	Cardiology	2.2 (2.0-2.5)	<0.001	2.6 (2.2-3.0)	<0.001	0.7 (0.6-0.8)	<0.001	0.5 (0.4-0.7)	<0.001	0.3 (0.3-0.4)	<0.001	0.2 (0.2-0.3)	<0.001
	Elderly Care	0.8 (0.7-0.9)	<0.001	1.2 (1.0-1.4)	0.0 36	1.9 (1.6-2.2)	<0.001	0.8 (0.7-1.1)	0.2 34	1.2 (1.0-1.4)	0.0 13	0.6 (0.5-0.7)	<0.001
	Other medical specialties	0.8 (0.8-0.9)	<0.001	1.2 (1.0-1.4)	0.0 13	1.2 (1.0-1.3)	0.0 23	0.7 (0.5-0.8)	<0.001	1.0 (0.9-1.1)	0.9 05	0.6 (0.5-0.7)	<0.001
	Surgery & Trauma	1.2 (1.1-1.3)	<0.001	1.6 (1.4-1.8)	<0.001	0.7 (0.6-0.8)	<0.001	0.5 (0.4-0.6)	<0.001	0.8 (0.7-1.0)	0.0 13	0.5 (0.4-0.5)	<0.001

334 All factors significant at $p < 0.05$ level in univariate analysis were included in the multivariate
 335 model. HFRS = hospital frailty risk score, LOS = length of stay

336

337

338 **Hospital Frailty Risk Score (HFRS) and antithrombotic** 339 **prescription**

340 As HFRS increased, OAC use did not significantly change but there was a clear decrease in
341 AP drug use either alone or with an OAC (-8.3% per group, linear regression $R^2 = 0.85$, $p <$
342 0.01 , Fig 2d). However in multivariate analysis increasing HFRS was strongly negatively
343 associated with OAC use, positively associated with DOAC use and positively associated
344 with AP drug use only.

345

346 **Relationship Between Discharging Specialty and OAC use**

347 We found a large variation in OAC prescribing rates between different specialities (Fig 2f).
348 The highest rate of OAC use was in patients discharged from cardiology (68.8%, $n=1048$),
349 with lower rates of OAC use in patients discharged under a surgical team (56.6%, $n=2768$), a
350 medical specialty (52.3%, $n=3196$), elderly care (46.8%, $n=1249$) and the stroke unit (42.0%,
351 $n=1222$). The relationship between discharge location and antithrombotic drug use remained
352 significant after correction for a range of clinical variables, age and HFRS (Table 4).

353

354 **Medication switching in AF patients**

355 We identified a group of 1708 patients ($CHA_2DS_2-VASc \geq 2$) with 2 or more admissions at
356 least 12 months apart. Of these 895 (52.4%) changed their antithrombotic medication status
357 (Fig 4a). Overall there was an increase in OAC use from 985 to 1069 patients (+8.5%) and a
358 net movement of patients to DOACs from warfarin and AP drugs. These findings were more

359 marked when only patients whose admissions straddled the 2014 NICE guidelines update
360 were included (1096 patients; Fig 4b).

361

362 **Fig 4. Medication switching in patients with $CHA_2DS_2-VASc \geq 2$ at last visit.** a) all visits
363 at least 12 months apart and b) last visit before vs last visit after the 2014 NICE guideline
364 update (b is a subset of a). Line width indicates overall proportion.

365

366

367 **Discussion**

368 We have developed a pipeline to calculate clinical risk scores from free-text using NLP.
369 Using this pipeline, we were able to estimate CHA₂DS₂-VASc and HAS-BLED risk scores
370 from free-text EHR data that are in line with those calculated manually and could scale up to
371 analyse data on over 10,000 AF patients managed at a multi-site large UK NHS Trust.

372
373 We were able to replicate the changes in antithrombotic drug practices observed over the last
374 7 years in previous registry-based observational studies. First, there has been a substantial
375 increase in the proportion of AF patients at high risk of stroke (CHA₂DS₂-VASc \geq 2)
376 prescribed an OAC, with OAC use rising from 42% in 2011 to 62% in 2017. Second, there
377 has been a reduction in the use of warfarin and an increase in DOAC prescription, such that
378 in 2017 more patients were discharged on a DOAC than warfarin. Third, the use of AP drugs
379 alone to prevent stroke has dropped significantly, from 40% in 2011 to 10% in 2017.

380

381 **Semantic NLP analysis of routinely-generated clinical data**

382 Clinical applications of NLP are an active research area. A recent systematic review
383 identified 71 NLP applications for clinical text, 12 of which are open-source.[22] We took
384 different approaches to NLP for the two major components of our study: extracting
385 medication from discharge summaries and detecting clinical concepts in text (to derive risk
386 scores). For medications, we use a series of regular expression rules tuned to the specific
387 prescription text used in this study with high precision but less generalizability. For risk
388 scoring, we built a concept mapping pipeline on top of an open-source clinical NLP tool
389 SemEHR[13], which can detect far more concepts than it is feasible to manually code rules

390 for, but with the trade-off that it is not specifically designed for any particular disease
391 concepts.

392

393 **Use of EHR data for retrospective and prospective applications in** 394 **cardiology**

395 EHRs have been increasingly used to support observational studies. However, typically this
396 involves the transcription of clinical data from EHRs into a registry-specific electronic case
397 report form, an approach with many of the limitations inherent of a classical observational
398 study. The development and maintenance of case registries is time-consuming, and the scope
399 of the research questions that can be answered are limited to the dataset defined *a priori*. By
400 using a domain-agnostic concept mapping pipeline (SemEHR) on unstructured text, our study
401 was able to test both conventional risk scores (CHA₂DS₂-VAsC) and a novel risk score
402 (HFRS).

403

404 Ours is not the first study to utilize unstructured EHR data in AF research.[15–17,23] Our
405 study builds on this previous work through the use of text data with an NLP pipeline, the
406 calculation of additional risk scores and an analysis of prescribing patterns. Whilst we
407 evaluate our pipeline in the context of AF, our aim is to provide an open tool for clinical risk
408 scoring calculations in general.

409

410 **Trends in Antithrombotic drug use**

411 Large retrospective population-based studies have established a clear trend of increased OAC
412 prescribing in AF patients, driven by uptake of DOACs.[6,7] Our ability to reproduce these

413 findings by applying NLP to unstructured EHR data strongly supports the validity of the NLP
414 pipeline. In our analysis, OAC prescription was independently associated with risk factors for
415 stroke and bleeding, consistent with the findings of other studies.

416
417 Despite a significant increase in OAC use during our study period, ~35% of patients at high
418 risk of stroke were still not prescribed an OAC indicating there are some remaining barriers
419 to OAC use. In our data, a documented bleeding problem (present in 14% of the cohort and
420 associated with 40% reduction in OAC use) and increasing frailty (Table 4) were independent
421 predictors of OAC underuse, suggesting that perceived risk of bleeding and risk of harm due
422 to OAC continues, particularly in elderly patients, to have a strong influence on the
423 antithrombotic drug decision-making process.[24–26]

424
425 HFRS proposed by Gilbert *et al.* [20] is a high-dimensional frailty score calculated from
426 ICD-10 diagnostic codes. When we evaluated antithrombotic drug prescription using HFRS
427 as a continuous variable and adjusting for other clinical variables and discharging specialty,
428 there was a significant relationship between HFRS and antithrombotic drug use (Table 4).
429 Patients with a higher HFRS were less likely to take an OAC, more likely to take a DOAC
430 (vs. warfarin) if they were on an OAC, and more likely to take an AP drug alone versus an
431 OAC. This suggests there is an underlying high-dimensional frailty characteristic influencing
432 clinician decision-making despite not being explicitly calculated.

433
434 The highest OAC prescription rates were in patients discharged from a cardiology ward
435 (n=1048, 69%), whereas OAC use was significantly lower in patients discharged from an
436 elderly care ward (n=1240, 47%) and other medical specialties (n=3196, 52%). Although in
437 part this may reflect the differing case mix of specialty patient populations, given the

438 magnitude of the differences seen even with multivariate correction of clinical variables
439 (including stroke and bleed risk factors and frailty risk score), it is likely that some of our
440 findings are due to specialty-specific behaviours in relation to AF and bleeding risk. This
441 suggests efforts to continue to increase OAC prescribing rates beyond current may be most
442 effective if targeted by clinical specialty.

443

444 **Limitations**

445 One of the major limitations of an EHR- and NLP-based approach, as used in our analysis, is
446 data accuracy. We manually validated the major variables in our analysis but the accuracy of
447 our NLP algorithm deserves closer scrutiny as there is a risk of causing a significant
448 degradation in data accuracy. Whilst the agreement between our algorithm and clinical
449 experts was high for CHA2DS2-VASc and fair for HAS-BLED, in all comparisons the
450 agreement between experts was higher. This gap represents room for improvement in the
451 algorithm primarily due to difficulty detecting some risk factors.

452

453 Retrospective assessment of the data source of many of the variables in the HAS-BLED score
454 is challenging irrespective of the approach used, with a previous study finding that inter-rater
455 reliability between human observers for some HAS-BLED components is low.[15] This
456 disagreement at the level of the data source is commonly described even with curated registry
457 data.[27] This limitation particularly affected the “uncontrolled hypertension” and “labile
458 INR” features of the HAS-BLED score, neither of which is reliably recorded or detected.
459 This leaves some comorbidity associated with bleeding risk unaccounted for in our
460 multivariate analysis.

461

462 Unlike the use of registry data, routine EHR data may not capture all necessary clinical
463 information on all patients, as this is a secondary use of the record. It is therefore possible
464 that we have missed important co-morbidities in some of the patients. This may have led to
465 an overall underestimation of co-morbidities in our patient population, as well as undermined
466 some of our analyses relating clinical variables to anti-thrombotic drug use.

467

468 The NLP algorithm was tested on data from one multi-site organization using three different
469 EHR systems over a 6-year period. While this may show a degree of generalizability, further
470 validation on data from other EHR systems in other organizations will be needed.

471

472 We used data from inpatient admissions as these more accurately record data on drug
473 prescriptions. As a result our patient population has the potential to be older and frailer, with
474 more comorbidity, than typical community AF cohorts. Although our population had similar
475 baseline characteristics to the populations in previous studies[28,29], not all co-morbidities
476 may be captured. This is a limitation is inherent in the design of all studies using routinely
477 generated non-curated data.

478

479 Our study did not attempt to distinguish between the different temporal patterns of atrial
480 fibrillation (permanent, persistent, paroxysmal). This is because these temporal patterns are
481 frequently not used in free text or used ambiguously (e.g. 'PAF' could mean any of the
482 terms). Nonetheless, national and international guidelines on anticoagulation for AF do not
483 have different anticoagulation recommendations for different temporal patterns.

484

485 Finally, our data is observational. Therefore, although we have demonstrated associations
486 between changes in antithrombotic drug use and a range of clinical variables, it is not
487 possible to conclude a causal link.

488

489 **Conclusion**

490 We present a novel open-source methodology for an automated pipeline to calculate risk
491 scores from NLP and track prescribing patterns, incorporating future disease entities, risk
492 profiles and ontologies. We have used this methodology to demonstrate significant changes
493 in antithrombotic practice in AF since the introduction of DOACs, in a large NHS Trust. The
494 tools used in this study are open-source and transparent (CogStack[12], SemEHR[14] and our
495 pipeline) allowing any other organization to validate on their own cohorts and optimize local
496 population health at low cost. This highlights the power of semantic NLP processing tools for
497 a disease-specific domain, but is generalizable to a variety of other diseases and use-cases,
498 and highlights the growing impact of health informatics in healthcare.[30]

499

500 **Acknowledgements**

501 DMB is funded by a UKRI Innovation Fellowship as part of Health Data Research UK
502 MR/S00310X/1 (<https://www.hdruk.ac.uk>). HW is funded by a UKRI Rutherford Fellowship
503 as part of Health Data Research UK MR/S004149/1. RB is funded in part by grant
504 MR/R016372/1 for the King's College London MRC Skills Development Fellowship
505 programme funded by the UK Medical Research Council (MRC, <https://mrc.ukri.org>) and by
506 grant IS-BRC-1215-20018 for the National Institute for Health Research (NIHR,
507 <https://www.nihr.ac.uk>) Biomedical Research Centre at South London and Maudsley NHS

508 Foundation Trust and King's College London. AMS is supported by the British Heart
509 Foundation (<https://www.bhf.org.uk>). NIHR Biomedical Research Centre funding to
510 SLAM/KCL and to GSTT/KCL in partnership with KCL. The BigData@Heart Consortium is
511 funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No.
512 116074 (<https://www.imi.europa.eu>). This Joint Undertaking receives support from the
513 European Union's Horizon 2020 research and innovation programme and EFPIA; it is
514 chaired, by DE Grobbee and SD Anker, partnering with 20 academic and industry partners
515 and ESC. This paper represents independent research part funded by the National Institute for
516 Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS
517 Foundation Trust and King's College London. The views expressed are those of the author(s)
518 and not necessarily those of the NHS, the NIHR or the Department of Health and Social
519 Care. The funders had no role in study design, data collection and analysis, decision to
520 publish, or preparation of the manuscript.

521

522 **Competing Interests**

523 I have read the journal's policy and the authors of this manuscript have the following
524 competing interests: Dr. Teo reports non-financial support from Bayer, grants from Bristol-
525 Meyers-Squibb, outside the submitted work; Dr. scott reports personal fees from Bayer,
526 outside the submitted work. All other authors declare that no competing interests exist. This
527 does not alter our adherence to PLOS ONE policies on sharing data and materials.

528

529 **References**

- 530 1. Yiin GSC, Howard DPJ, Paul NLM, Li L, Mehta Z, Rothwell PM, et al. Recent time
531 trends in incidence, outcome and premorbid treatment of atrial fibrillation-related
532 stroke and other embolic vascular events: a population-based study. *J Neurol*
533 *Neurosurg Psychiatry*. 2015/10/20. 2017;88: 12–18. doi:10.1136/jnnp-2015-311947
- 534 2. NICE. Atrial fibrillation: management (Aug 2014 update) [Internet]. 2014.
- 535 3. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining Clinical Risk
536 Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using
537 a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation.
538 *Chest*. 2010;137: 263–272. doi:10.1378/chest.09-1584
- 539 4. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A Novel User-
540 Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients
541 With Atrial Fibrillation: The Euro Heart Survey. *Chest*. 2010;138: 1093–1100.
542 doi:10.1378/chest.10-0134
- 543 5. Cowan C, Healicon R, Robson I, Long WR, Barrett J, Fay M, et al. The use of
544 anticoagulants in the management of atrial fibrillation among general practices in
545 England. *Heart*. 2013;99: 1166–1172. doi:10.1136/heartjnl-2012-303472
- 546 6. Campbell Cowan J, Wu J, Hall M, Orłowski A, West RM, Gale CP. A 10 year study of
547 hospitalized atrial fibrillation-related stroke in England and its association with uptake
548 of oral anticoagulation. *Eur Heart J*. 2018; doi:10.1093/eurheartj/ehy411
- 549 7. Lacoïn L, Lumley M, Ridha E, Pereira M, McDonald L, Ramagopalan S, et al.
550 Evolving landscape of stroke prevention in atrial fibrillation within the UK between
551 2012 and 2016: a cross-sectional analysis study using CPRD. *BMJ Open*. 2017;7:

- 552 e015363. doi:10.1136/bmjopen-2016-015363
- 553 8. Holt TA, Hunter TD, Gunnarsson C, Khan N, Cload P, Lip GYH. Risk of stroke and
554 oral anticoagulant use in atrial fibrillation: A cross-sectional survey. *Br J Gen Pract.*
555 2012; doi:10.3399/bjgp12X656856
- 556 9. Hemingway H, Asselbergs FW, Danesh J, Dobson R, Maniadakis N, Maggioni A, et
557 al. Big data from electronic health records for early and late translational
558 cardiovascular research: challenges and potential. *Eur Heart J.* 2017;39: 1481–1495.
559 doi:10.1093/eurheartj/ehx487
- 560 10. Kharrazi H, Anzaldi LJ, Hernandez L, Davison A, Boyd CM, Leff B, et al. The Value
561 of Unstructured Electronic Health Record Data in Geriatric Syndrome Case
562 Identification. *J Am Geriatr Soc.* 2018;66: 1499–1507. doi:10.1111/jgs.15411
- 563 11. Jackson R, Kartoglu I, Stringer C, Gorrell G, Roberts A, Song X, et al. CogStack -
564 Experiences of deploying integrated information retrieval and extraction services in a
565 large National Health Service Foundation Trust hospital. *BMC Med Inform Decis*
566 *Mak.* 2018; doi:10.1186/s12911-018-0623-9
- 567 12. CogStack. CogStack Pipeline [Internet]. 2019. Available:
568 <https://github.com/CogStack/CogStack-Pipeline>
- 569 13. Wu H, Toti G, Morley KI, Ibrahim ZM, Folarin A, Jackson R, et al. SemEHR: A
570 general-purpose semantic search system to surface semantic data from clinical notes
571 for tailored care, trial recruitment, and clinical research. *J Am Med Informatics Assoc.*
572 2018; doi:10.1093/JAMIA/OCX160
- 573 14. Wu H. CogStack-SemEHR [Internet]. p. 2019.
- 574 15. Wang S V, Rogers JR, Jin Y, Fischer MA, Bates DW. Use of electronic healthcare

- 575 records to identify complex patients with atrial fibrillation for targeted intervention. J
576 Am Med Informatics Assoc. 2016;24: 339–344. doi:10.1093/jamia/ocw082
- 577 16. Grouin C, Deléger L, Rosier A, Temal L, Dameron O, Van Hille P, et al. Automatic
578 computation of CHA2DS2-VASc score: information extraction from clinical texts for
579 thromboembolism risk assessment. AMIA . Annu Symp proceedings AMIA Symp.
580 2011;
- 581 17. Rosier A, Mabo P, Temal L, Van Hille P, Dameron O, Deléger L, et al. Personalized
582 and automated remote monitoring of atrial fibrillation. Europace. 2016;
583 doi:10.1093/europace/euv234
- 584 18. U.S. National Library of Medicine. Unified Medical Language System (UMLS)
585 [Internet]. Available: <https://www.nlm.nih.gov/research/umls/>
- 586 19. Köhler S, Carmody L, Vasilevsky N, Jacobsen JOB, Danis D, Gourdine JP, et al.
587 Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources.
588 Nucleic Acids Res. 2019; doi:10.1093/nar/gky1105
- 589 20. Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, et al. Development
590 and validation of a Hospital Frailty Risk Score focusing on older people in acute care
591 settings using electronic hospital records: an observational study. Lancet. 2018;
592 doi:10.1016/S0140-6736(18)30668-8
- 593 21. Whetzel PL, Noy NF, Shah NH, Alexander PR, Nyulas C, Tudorache T, et al.
594 BioPortal: Enhanced functionality via new Web services from the National Center for
595 Biomedical Ontology to access and use ontologies in software applications. Nucleic
596 Acids Res. 2011; doi:10.1093/nar/gkr469
- 597 22. Kreimeyer K, Foster M, Pandey A, Arya N, Halford G, Jones SF, et al. Natural

- 598 language processing systems for capturing and standardizing unstructured clinical
599 information: A systematic review. *Journal of Biomedical Informatics*. 2017.
600 doi:10.1016/j.jbi.2017.07.012
- 601 23. Piazza G, Hurwitz S, Galvin CE, Harrigan L, Baklla S, Hohlfelder B, et al. Alert-based
602 computerized decision support for high-risk hospitalized patients with atrial fibrillation
603 not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). *Eur Heart*
604 *J*. 2019; doi:10.1093/eurheartj/ehz385
- 605 24. Bahri O, Roca F, Lechani T, Druesne L, Jouanny P, Serot J-M, et al. Underuse of Oral
606 Anticoagulation for Individuals with Atrial Fibrillation in a Nursing Home Setting in
607 France: Comparisons of Resident Characteristics and Physician Attitude. *J Am Geriatr*
608 *Soc*. 2015;63: 71–76. doi:10.1111/jgs.13200
- 609 25. Lefebvre M-CD, St-Onge M, Glazer-Cavanagh M, Bell L, Kha Nguyen JN, Viet-Quoc
610 Nguyen P, et al. The Effect of Bleeding Risk and Frailty Status on Anticoagulation
611 Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study. *Can J*
612 *Cardiol*. 2016;32: 169–176. doi:10.1016/j.cjca.2015.05.012
- 613 26. Pilotto A, Gallina P, Copetti M, Pilotto A, Marcato F, Mello AM, et al. Warfarin
614 Treatment and All-Cause Mortality in Community-Dwelling Older Adults with Atrial
615 Fibrillation: A Retrospective Observational Study. *J Am Geriatr Soc*. 2016/06/13.
616 2016;64: 1416–1424. doi:10.1111/jgs.14221
- 617 27. Faxon DP, Burgess A. Cardiovascular Registries: Too Much of Good Thing?
618 *Circulation. Cardiovascular interventions*. United States; 2016. p. e003866.
619 doi:10.1161/CIRCINTERVENTIONS.116.003866
- 620 28. Marzec LN, Wang J, Shah ND, Chan PS, Ting HH, Gosch KL, et al. Influence of
621 Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. *J*

622 Am Coll Cardiol. 2017;69: 2475–2484. doi:<https://doi.org/10.1016/j.jacc.2017.03.540>

623 29. Fosbol EL, Holmes DN, Piccini JP, Thomas L, Reiffel JA, Mills RM, et al. Provider
624 specialty and atrial fibrillation treatment strategies in United States community
625 practice: findings from the ORBIT-AF registry. J Am Heart Assoc. 2013;2: e000110–
626 e000110. doi:10.1161/JAHA.113.000110

627 30. Topol EJ. High-performance medicine: the convergence of human and artificial
628 intelligence. Nat Med. 2019;25: 44–56. doi:10.1038/s41591-018-0300-7

629

630

631

632 **Supporting information**

633 **S1 Table. Definition of HAS-BLED and CHA₂DS₂-VASc as used in this study.** Age and
634 gender are included directly from electronic health record data. The agreed terms under
635 “include” and “exclude” headings were used by clinical experts to calculate each score
636 manually. The lists of UMLS concepts for each component were derived automatically and
637 used by the NLP scoring algorithm.

638

639 **S2 Table. Performance of the NLP pipeline for each component of CHA₂DS₂-VASc and**
640 **HAS-BLED.** Cases were considered positive if at least one manual rater marked as positive.
641 The agreement between the two manual raters is shown as “agreement between raters”.

642

643 **S3 Table. Total score and component score for CHA₂DS₂-VASc and HAS-BLED.** Each
644 row represents a single patient identified only by row number (“Patient” column).

645

646

647

648


649

650

651

652

653 Figure 1.



654

655

656

657

658

659

660

661

662


663

664

665

666

667 Figure 2.



668

669

670

671

672

673


674

675

676

677

678 Figure 3.



679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699 Figure 4.

